A new course of action:
Treating Functional Cellular Deficits
RepliCel is a regenerative medicine company focused on developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function. The company’s RCT-01, RCS-01, and RCH-01 cell therapies are designed to treat chronic tendinosis, damaged or aging skin, and pattern baldness.
Shiseido Company, Limited has an exclusive license for RCH-01 in certain Asian countries including Japan, China and South Korea.
All product candidates are based on RepliCel’s innovative technology utilizing cell populations isolated from a patient’s own healthy hair follicles. The company is also developing a propriety injection device optimized for the administration of its products and licensable for use with other dermatology applications. The company’s product pipeline is comprised of multiple clinical trials all anticipated to launch in 2015 in addition to Shiseido's own clinical trial of RCH-01 and the device in late prototype development.
January 20, 2015
January 7, 2015
December 22, 2014
February 20, 2015
February 4, 2015
January 28, 2015